- Home
- CRTO vs PTGX Comparison
CRTO vs PTGX Comparison
Compare CRTO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRTO | PTGX |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 5.4B |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CRTO | PTGX |
|---|---|---|
| Price | $20.08 | $89.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $38.67 | ★ $90.56 |
| AVG Volume (30 Days) | 572.9K | ★ 982.6K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.79 | N/A |
| EPS | ★ 3.00 | 0.72 |
| Revenue | ★ $1,956,800,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.42 | $288.98 |
| P/E Ratio | ★ $6.68 | $123.27 |
| Revenue Growth | ★ 0.53 | N/A |
| 52 Week Low | $19.00 | $33.70 |
| 52 Week High | $47.27 | $96.54 |
Technical Indicators
Market Signals| Indicator | CRTO | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 55.09 |
| Support Level | $19.41 | $84.11 |
| Resistance Level | $20.51 | $90.00 |
| Average True Range (ATR) | 0.82 | 3.27 |
| MACD | 0.01 | -0.65 |
| Stochastic Oscillator | 31.16 | 41.92 |
Price Performance
Historical ComparisonAbout CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.